No, research and development is not part of SG&A. Under standard financial reporting, R&D sits on its own line of the income statement, separate from selling, general, and administrative expenses, because the two categories describe fundamentally different spending. SG&A is the cost of running the business you have today. R&D is spending on the products, processes, and technology you hope to have tomorrow.
What SG&A Actually Contains
Selling, general, and administrative expenses are the overhead of operating a business that isn’t tied directly to making a product. The selling side covers advertising, sales salaries and commissions, and outbound shipping. The general and administrative side covers executive pay, accounting and legal, office rent, utilities, insurance, and HR. All of it supports current operations.
Because SG&A reflects day-to-day overhead, analysts read it as a measure of operational efficiency. When SG&A grows faster than revenue, a company is spending more to sustain the business it already has.
What Counts as R&D
R&D covers the cost of discovering new knowledge and turning it into new products or processes. That includes salaries for research staff, materials consumed in prototype testing, depreciation on lab equipment, and payments to outside contractors performing qualified research.
Plenty of work that sounds like development doesn’t qualify. Under U.S. GAAP, ASC 730 excludes routine product tweaks, market research, quality control testing, and activities in extractive industries such as mining exploration. Software built for a company’s own selling or administrative use isn’t R&D either; it follows separate rules under ASC 350-40.
Why the Two Are Reported Separately
Combining R&D into SG&A would hide information investors need. A pharmaceutical company spending 20% of revenue on drug development and 15% on overhead looks nothing like one spending 5% on R&D and 30% on overhead, even if their total operating costs match. Merged, they’d read the same.
U.S. GAAP doesn’t strictly require R&D to appear as a named line on the face of the income statement, but ASC 730-10-50-1 requires companies to disclose total R&D costs charged to expense for each period presented, including R&D for software products intended for sale or licensing.1Internal Revenue Service. FAQs – IRC 41 QREs and ASC 730 LBI Directive In practice, nearly every public company shows R&D as its own line because the SEC expects clear disclosure and pushes back when R&D is buried in broader categories. SEC staff have specifically focused on the quality of R&D disclosures, often asking companies to break spending down by major product or project category.2PwC Viewpoint. Research and Development: SEC Staff Comments If a filer aggregates R&D with other operating expenses on the face of the statement, the R&D total still has to be broken out elsewhere in the filing.
How R&D Is Recognized
The default rule under U.S. GAAP is simple: expense R&D in the period it’s incurred. You don’t capitalize it as a balance-sheet asset, because there’s no guarantee a given project ever produces a commercially viable product. Immediate expensing keeps earnings and assets conservative.
Two narrow exceptions exist. Equipment and facilities bought for R&D that have an alternative future use can be capitalized and depreciated normally. Intangible assets acquired in a business combination, such as in-process R&D from an acquisition, are capitalized regardless of alternative use. For internally generated R&D, though, the cost hits the income statement right away, on its own line, not inside SG&A.
Software: The Common Gray Area
Software costs trip companies up because the rules depend on what the software is for. Software developed to sell or license to customers is treated as R&D and expensed until it reaches “technological feasibility”; costs after that milestone are capitalized until the product is ready for release.1Internal Revenue Service. FAQs – IRC 41 QREs and ASC 730 LBI Directive
Internal-use software follows ASC 350-40. Preliminary-stage costs are expensed, application-development costs are capitalized, and post-implementation costs like maintenance are expensed again. Because internal-use software supports selling or administrative activities, it sits outside ASC 730, so it wouldn’t appear in the R&D line even when the underlying work looks technical.
The IFRS Boundary
If you’re reading statements prepared under International Financial Reporting Standards, the classification question still has the same answer, but the numbers can move. IAS 38 splits R&D into two phases. Research costs are expensed. Development costs can be capitalized once technical and commercial feasibility are demonstrated, then amortized. Two companies doing identical work can therefore report different figures depending on the framework, and the IFRS company will show a development asset on the balance sheet that its GAAP counterpart never records.
Why the Separation Matters for Analysis
Keeping R&D and SG&A apart supports two metrics analysts rely on. R&D intensity, calculated as R&D expense divided by revenue, shows how aggressively a company is investing in future growth. SG&A as a percentage of revenue shows how well management is controlling overhead. Merge them and a heavy R&D spender looks operationally bloated when it’s actually funding a pipeline.
That matters most within an industry. A biotech spending 40% of revenue on R&D and 12% on SG&A is making a deliberate bet on drug development. A competitor at 15% R&D and 25% SG&A has a different strategy and a different cost problem. Combined figures obscure both. To judge whether a company is building future value or just accumulating overhead, you need to see each number on its own, which is exactly why the income statement keeps them apart.